comparemela.com

Latest Breaking News On - Founded entities - Page 1 : comparemela.com

PRTC s Akili Enters Into Merger Agreement | Company Announcement

Investegate announcements from PRTC's Akili Enters Into Merger Agreement

United kingdomUnited statesRob winderNichole bobbynIan stoneDan elenbaasMatt franklinBen atwellAkili incPuretech healthAlpha merger sub incInizio evoke communicationsVirtual therapeutics corporation parentAkili investor relations departmentBaker mckenzieGoodwin procter

PRTC to Present at Jefferies Healthcare Conference | Company Announcement

Investegate announcements from PRTC to Present at Jefferies Healthcare Conference

United kingdomEric elenkoNichole bobbynRob winderBharatt chowriraBen atwellPuretech healthTech healthJefferies global healthcareChief executive officerJefferies global healthcare conferenceFounded entitiesPrivate securities litigation reform actAnnual report

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON (BUSINESS WIRE) May 23, 2024

United statesBen atwellNichole bobbynBharatt chowriraRob winderEric elenkoPuretech healthTech healthChief executive officerJefferies global healthcare conferenceBusiness wireFounded entitiesNote regarding forward looking statementsPrivate securities litigation reform actAnnual report

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C difficile Infection

VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection .

United kingdomJeffrey silberPaul feuerstadtPuretech healthDevelopment authorityBiomedical advanced researchUs department of healthDrug administrationYale university school of medicineAdministration for strategic preparednessHuman servicesFounded entityVedanta biosciencesBiologics license applicationBiosciences enrolls first patientPivotal phase

PRTC s Vedanta Begins Phase 3 of VE303 in C diff | Company Announcement

Investegate announcements from PRTC's Vedanta Begins Phase 3 of VE303 in C. diff

United kingdomPaul feuerstadtNichole bobbynJeffrey silberBen atwellRob winderBiomedical advanced researchHuman servicesYale university school of medicineDevelopment authorityDrug administrationAdministration for strategic preparednessUs department of healthPuretech healthPivotal phaseTech health

vimarsana © 2020. All Rights Reserved.